ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma.

Authors

Wangyu Chen, Haiming Li, Jie Zeng, Guijing Xie, Zhibo Chen, Xie Xu, Wenjie Bai, Gang Xiao, Jianjiang Xie

Published in

PeerJ. Volume 14. Pages e21347. Epub Jun 17, 2026.

Abstract

A considerable proportion of patients with early-stage lung adenocarcinoma (esLUAD) experience recurrence after curative resection, highlighting the need for improved biomarkers. Current biomarkers such as PD-L1 and tumor mutational burden (TMB) have limited predictive utility in early-stage disease. Through an unbiased screening approach, endoplasmic reticulum oxidoreductase 1α (ERO1A) was identified as a candidate gene for further investigation.
Multi-omics data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were integrated. Machine learning algorithms (least absolute shrinkage and selection operator (LASSO), random forest (RF), support vector machine (SVM)) were employed to identify core prognostic genes. Functional enrichment, immune microenvironment analysis, and drug sensitivity prediction were conducted. Key findings were validated using immunohistochemistry (IHC) in an independent institutional cohort.
ERO1A was identified as a robust, independent predictor of poor overall and recurrence-free survival in esLUAD. It was significantly upregulated in tumors and associated with enhanced proliferative pathways. Paradoxically, high ERO1A expression correlated with an immune-activated tumor microenvironment, characterized by enriched CD8 + T cell infiltration, reduced M2 macrophages, and increased mature tertiary lymphoid structures. ERO1A-high tumors exhibited elevated TMB and PD-L1 levels, and were associated with superior response to immune checkpoint inhibitors in validation cohorts. Bioinformatic analysis suggested that ERO1A-high tumors might exhibit resistance to conventional chemotherapy while showing potential sensitivity to epidermal growth factor receptor (EGFR)-targeted therapies, though this was not confirmed in clinical validation.
ERO1A expression stratifies lung adenocarcinoma (LUAD) into distinct subsets with divergent therapeutic implications. It represents a promising biomarker for prognostic stratification and immunotherapy selection, supporting its potential clinical utility in guiding peri-operative therapy decisions.

PMID:
42328676
Bibliographic data and abstract were imported from PubMed on 22 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.